quinta-feira, 5 de novembro de 2026
PesquisarExplore
Via News Knowledge File

Chevron Corporation

organization80% conf.·synced Nov 5, 2026

Integrated energy company with upstream and downstream operations globally, stock ticker CVX

60
sourced metrics
612
relationships
20
stated objectives
4
Via News reports

Every fact below is drawn from Via News's knowledge graph and linked to the source document it came from. Nothing here is unsourced. How we source →

Key metrics · each point sourced

Stock Return Ytd
39.2%
Nov 4, 2026reference only
Price 52 Week High
235.52USD
Nov 4, 2026reference only
Stock Price
216.96USD
Nov 4, 2026reference only
Market Cap
428663335607USD
Nov 4, 2026reference only
Price 52 Week Low
146.75USD
Nov 4, 2026reference only
Revenue
70055000000.0USD
Jun 30, 2026reference only
Eps
6.11USD_per_share
Jun 30, 2026reference only
Shares Outstanding
1975771274.0shares
Jun 30, 2026reference only
Total Assets
330135000000.0USD
Jun 30, 2026reference only
Net Income
12072000000.0USD
Jun 30, 2026reference only
Cost Of Revenue
36607000000.0USD
Jun 30, 2026reference only
Total Liabilities
134577000000.0USD
Jun 30, 2026reference only
Stockholders Equity
189883000000.0USD
Jun 30, 2026reference only
Operating Cash Flow
2514000000.0USD
Mar 31, 2026reference only
Rd Expense
427000000.0USD
Dec 31, 2025reference only

Stated objectives

Achieve $3-4 billion cost reduction in 2026

source
target: $3-4 billion stated

Offshore production increase of approximately 200,000 bbl/day in 2026

source
target: ~200,000 bbl/day stated

Target doubled shale/tight recovery through stimulation program

source
target: 2x recovery stated

Return cash to shareholders through dividends and buybacks

source
target: $6B per quarter stated

Complete Hess acquisition integration and unlock synergies

source
stated

Maintain record production levels above 4M BOE/day

source
target: 4.086M BOE/day stated

Achieve structural cost reductions of $3-4B

source
target: 3-4 billion USD by 2026-12-31 00:00:00stated

Achieve $1B run-rate synergies from Hess acquisition

source
target: 1 billion USD by 2025-12-31 00:00:00stated

Reach 1M BOE/day production in Permian Basin

source
target: 1000000 BOE per day by 2025-12-31 00:00:00stated

Chevron plateau production target in the Bakken

source
target: 200,000 barrels oil equivalent per day stated

Relationship graph · 612 connections

operates in
85
located in
77
Competes with
68
Covered by
54
Employs
52
acquired by
39
Owns
34
Invested in
29

Where sources disagree

We surface conflicts between sources rather than hiding them.

value conflictunresolved

Both facts give Chevron's net_income for Q3 2024, observed at the same date (2024-09-30), but the values differ: 4,487,000,000 USD vs 4.6 billion USD. Rounding 4.487B gives 4.5B, not 4.6B, so the gap (about 113M, roughly 2.5%) is not a rounding artifact. The likely cause is two sources or bases, such as GAAP net income versus an adjusted/non-GAAP figure, but the facts alone do not show which is correct.

Via News coverage

This Knowledge File is assembled from Via News's source-traceable knowledge graph. Metrics, objectives and relationships are extracted from primary and credible secondary documents and refreshed on a schedule. Read our methodology →
O que sabemos · a inteligência por trás desta página
Ao vivo do substrato
O que estamos a ver
Q4 2026 Oncology Data Season and Biotech Capital Allocation: ESMO Readouts, Ivonescimab PDUFA, and Diverging Corporate Moves
Late-2026 biotech is driven by a dense catalyst calendar. ESMO 2026 delivers data from ivonescimab, Enhertu, R-DXd and bemarituzumab, and the FDA has set a 14 Nov PDUFA date for the ivonescimab BLA. Capital allocation is diverging. Krystal Biotech authorized a $400M buyback while lowering FY2026 spend guidance and pushing milestones into 2027. Spago is moving to delist from Nasdaq First North. The facts are clinical and corporate events, not AI or fintech, so the finance angle is limited to capital markets (buybacks, guidance, delistings, regulatory timelines).
A nossa leitura dos dados ›
Sinais que acompanhamos
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Padrões que observamos ›
Onde as fontes divergem
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
Sinalizamos conflitos abertamente ›
Verificado recentemente
✓ Verificado com a fonte original
4,995
factos rastreados à sua fonte — e sinalizamos os que não se confirmam.
101 entidades acompanhadas4,995 factos verificados com a fonte5,549 documentos-fonte arquivados
Consulte estes dados → isubstrate.com